AmberGen, Inc.

AmberGen, Inc. is a development-stage Proteomics Company based in Waltham, Massachusetts. Dr. Kenneth Rothschild founded the company to develop tools for drug discovery and diagnostic assays based on in-vitro protein expression, photo cleavable linkers and novel labeling techniques. Several products are under development from this platform technology.
The Molecular Therapeutics Division in Waltham allows the technology to be applied to rapidly validate genes in disease associated pathways using a focused systems biology approach. This will enable novel drug targets to emerge whose biological functions are known, leading to the development of cell based assays for the screening of lead compounds. As part of this discovery, the mechanistic role of disease associated SNPs within these genes are being resolved in an effort to determine their effect on diversity and drug interactions. The Division is focused on asthma, osteoporosis and Alzheimer's disease.

Contact Details: 100 Beaver Street Waltham Massachusetts 02453-8425 United States of America Tel: 781-419-4055 Fax: Email: with@ambergen.com WWW: www.ambergen.com/

Loading...

BioNews Results for AmberGen, Inc.:
WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biolo	Pharma Live:  Nov 7 2009 8:35PM Matching: ambergen inc
WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biolo	Genetic Engineering News:  Nov 5 2009 7:49PM Matching: ambergen inc
WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board	Red Orbit:  Nov 5 2009 4:38PM Matching: ambergen inc
WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biolo	TickerTech.com:  Nov 5 2009 1:53PM Matching: ambergen inc

AmberGen, Inc. Patents:
US Patent No.	Title
7595198	Photocleavable isotope-coded affinity tags
6596481	Dual markers
6875592	Methods for the detection, analysis and isolation of nascent proteins
7057031	Nucleotide compositions comprising photocleavable markers and methods of preparation thereof
7101662	N-terminal and C-terminal markers in nascent proteins
→View more AmberGen, Inc. patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 880 times since April 2007, the link to the organisation's website has been followed 137 times

Recent Search Terms used to find this page: AMBERGEN INC 100 beaver street | ambergen | ambergen | ambergen | ambergen | ambergen inc | Ambergen | ambergen | .

Search for more companies in Waltham

Search for more companies in Massachusetts

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for AmberGen, Inc.